# The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

> **NCT05061628** · PHASE1 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 176 (estimated)

## Conditions studied

- Advanced Tumors

## Interventions

- **DRUG:** JS006 as Monotherapy
- **DRUG:** JS006 in combination with Toripalimab

## Key facts

- **NCT ID:** NCT05061628
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-21
- **Primary completion:** 2023-08-14
- **Final completion:** 2024-09-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061628, "The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05061628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*